Biomarkers Enhance Discrimination and Prognosis of Type 2 Myocardial Infarction.

Yu Horiuchi,Nicholas Wettersten,Mitul Patel,Christian Mueller,Sean-Xavier Neath,Robert H. Christenson,Nils G. Morgenthaler,James McCord,Richard M. Nowak,Gary M. Vilke,Lori B. Daniels,Judd E. Hollander,Fred S. Apple,Chad M. Cannon,John T. Nagurney,Donald Schreiber,Christopher DeFilippi,Christopher Hogan,Deborah B. Diercks,Gary F. Headden,Alexander T. Limkakeng,Inder S. Anand,Alan H.B. Wu,Stefan Ebmeyer,Allan S. Jaffe,W. Frank Peacock,Alan S. Maisel

Biomarkers Enhance Discrimination and Prognosis of Type 2 Myocardial Infarction.

2020

Background: The observed incidence of type 2 myocardial infarction (T2MI) is expected to increase with the implementation of increasingly sensitive cardiac troponin (cTn) assays. However, it remain...

Keywords:

Medicine
Observed Incidence
Myocardial infarction
Cardiology
cardiac troponin
Biomarker (medicine)
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations